404-02-010 ISMRM Abstract

Characterizing mutant IDH glioma and their treatment responses in vivo using proton MRS and deuterated α-ketoglutarate

Primary: Preclinical Animal & in vitro MR - Biomarkers

Secondary: Neuro - Tumors

404-02-010 · Altered Metabolism Across Healthy Aging and Neurological Disorders · Tuesday, 12 May, 8:20 AM–10:10 AM · Ballroom East

Keywords: Treatment Response Biomarkers Preclinical MRS Brain tumor Cancer metabolism

Accepted

Donghyun Hong ¹, Peder Larson¹, Sabrina Ronen¹

¹Department of Radiology and Biomedical Imaging, University Of California, San Francisco (UCSF), United States of America

Presenting Author: Donghyun Hong

Synopsis

Motivation:

Goals:

Approach:

Results:

Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

References

1. Chaumeil MM, Larson PE, Yoshihara HA, Danforth OM, Vigneron DB, Nelson SJ, Pieper RO, Phillips JJ, Ronen SM. Non-invasive in vivo assessment of IDH1 mutational status in glioma. Nature communications 2013;4(1):2429.

2. Hong D, Kim Y, Mushti C, Minami N, Wu J, Cherukuri MK, Swenson RE, Vigneron DB, Ronen SM. Monitoring Response to a Clinically Relevant IDH Inhibitor in Glioma – Hyperpolarized 13C Magnetic Resonance Spectroscopy Approaches. Neuro-Oncology Advances 2023.

3. Rich LJ, Bagga P, Wilson NE, Schnall MD, Detre JA, Haris M, Reddy R. 1H magnetic resonance spectroscopy of 2H-to-1H exchange quantifies the dynamics of cellular metabolism in vivo. Nature biomedical engineering 2020;4(3):335-342.

4. Cember AT, Wilson NE, Rich LJ, Bagga P, Nanga RPR, Swago S, Swain A, Thakuri D, Elliot M, Schnall MD. Integrating 1H MRS and deuterium labeled glucose for mapping the dynamics of neural metabolism in humans. Neuroimage 2022;251:118977.

5. Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, Yang X-L, Mashimo T, Raisanen JM, Marin-Valencia I. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nature medicine 2012;18(4):624-629.

6. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magnetic resonance in medicine 1993;30(6):672-679.

7. Molloy AR, Najac C, Viswanath P, Lakhani A, Subramani E, Batsios G, Radoul M, Gillespie AM, Pieper RO, Ronen SM. MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma. Theranostics 2020;10(19):8757.

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/404-02-010